A5002239887- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- CNS Lymphoma Diagnosis and Treatment
- Chronic Lymphocytic Leukemia Research
- Glioma Diagnosis and Treatment
- Viral-associated cancers and disorders
- Cancer Genomics and Diagnostics
- Acute Myeloid Leukemia Research
- Biosimilars and Bioanalytical Methods
- Hematological disorders and diagnostics
- T-cell and Retrovirus Studies
- Acute Lymphoblastic Leukemia research
- COVID-19 and healthcare impacts
- Virus-based gene therapy research
- Monoclonal and Polyclonal Antibodies Research
- SARS-CoV-2 and COVID-19 Research
- Multiple and Secondary Primary Cancers
- Cutaneous lymphoproliferative disorders research
- Immunotherapy and Immune Responses
- Bone and Joint Diseases
- Heparin-Induced Thrombocytopenia and Thrombosis
- Moyamoya disease diagnosis and treatment
- Cancer Immunotherapy and Biomarkers
- Integrated Circuits and Semiconductor Failure Analysis
- Chronic Myeloid Leukemia Treatments
Brown University
2016-2025
Lifespan
2016-2025
Rhode Island Hospital
2015-2024
Providence College
2018-2023
Miriam Hospital
2015
This retrospective case series study examines immune response of adults with hematologic malignant disease who were vaccinated 1 3 FDA-authorized COVID-19 vaccines between February and April 2021.
Background Patients with hematologic malignancies have impaired humoral immunity secondary to their malignancy and its treatment, placing them at risk of severe coronavirus disease‐19 (COVID‐19) infection reduced response vaccination. Methods The authors retrospectively analyzed serologic responses initial booster COVID‐19 vaccination in 378 patients subsequently tracked COVID‐19–related outcomes. Results Seroconversion occurred 181 (48%) after vaccination; who had active or those were...
Most patients receiving chimeric antigen receptor T-cell therapy (CAR-T) for aggressive B-cell non-Hodgkin lymphoma (B-NHL) do not experience a durable remission. Several novel agents are approved to treat relapsed, refractory B-NHL; however, it remains unclear how sequence these therapies pre- and post-CAR-T. We conducted multicenter retrospective analysis describe peri-CAR-T practice patterns survival predictors CD19-directed CAR-T. Patients (n = 514) from 13 centers treated with CAR-T...
Chimeric antigen receptor (CAR) T-cell (CAR-T) immunotherapy is an effective therapy for relapsed/refractory B-cell non-Hodgkin lymphoma (r/r B-NHL). However, data are limited on the impact of convergence race and social determinants health outcomes patients treated with CAR-T therapy. We examined interactions between insurance type care use in aggressive B-NHL. Adult r/r B-NHL CD19 CAR-Ts were identified 2015 2021 across 13 US academic centers. Insurance type, demographic, clinical...
There is a paucity of large-scale data delineating outcomes and prognostication older patients with primary central nervous system lymphoma (PCNSL). We retrospectively analyzed 539 newly-diagnosed PCNSL ages ≥60 years across 20 U.S. academic centers. The median age was 70 (range 60-88); at least one geriatric syndrome present in 46%; the Cumulative Index Ratings Scale-Geriatrics (CIRS-G) score 6 (range, 0-27); 36% had impairment activities daily living (ADL). most common induction regimens...
Classic Hodgkin lymphoma (cHL) treatment paradigms are undergoing a shift with the integration of immune checkpoint inhibitors (ICIs) into both first-line and relapsed/refractory (R/R) regimens. In therapy, synergy between ICIs chemotherapy may surpass previous standards ABVD BV-AVD established by landmark trials including RATHL ECHELON-1. R/R disease, combination has begun to challenge paradigm as bridge consolidative autologous stem cell transplantation. The clinical advances heralded ICI...
Abstract The diagnosis of parenchymal central nervous system (CNS) invasion and prediction risk for future CNS recurrence are major challenges in the management aggressive lymphomas, accurate biomarkers needed to supplement clinical predictors. For this purpose, we studied results a next-generation sequencing (NGS)–based assay that detects tumor-derived DNA clonotypic immunoglobulin gene rearrangements cerebrospinal fluid (CSF) patients with lymphomas. Used as diagnostic tool, NGS-minimal...
Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this prognostic impact. In multicenter retrospective study, we sought to confirm observation by evaluating survival outcomes among patients relapsed/refractory DHL DEL treated evaluate of relapse post-CART. A total 408 adult from 13 academic centers were included based on the availability DEL. All in (n = 80) vs non-DHL 328) analysis, while 333 analysis 74) non 179). On MVA,...
In aggressive lymphomas, discrepancies in survival reported from experimental and observational studies may reflect selective non-enrolment of high-risk patients trials. We examined the association between time diagnosis to chemotherapy overall diffuse large B-cell (DLBCL), Burkitt (BL), mantle cell (MCL) peripheral T-cell lymphoma (PTCL), using National Cancer Data Base records 130 549 treated 2004-2014. Across histologies, who started within 7 days had more often high International...
TPS7588 Background: First-line therapy for high-burden FL and MZL includes immunochemotherapy (most commonly rituximab with bendamustine), which is associated toxicities, not curative, leads to a prolonged T-cell depletion. The alternative of full-dose lenalidomide did improve efficacy or toxicity [Morschhauser et al., NEJM 2018]. However, lower-dose, short-course (15mg) may enhance cytotoxic immunity [Zucca al, Blood 2019]. Mosunetuzumab CD20xCD3-binding, T-cell-engaging bispecific antibody...
Using data from the National Cancer Data Base, 2010-2015, we examined characteristics and outcomes of T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL, N = 622) relative to unspecified diffuse (DLBCL-NOS, 91,588) nodular lymphocyte-predominant Hodgkin (NLPHL, 2240). Socio-demographic patients with THRLBCL resembled more NLPHL than DLBCL-NOS. Five-year overall survival in was 66% (95% confidence interval [CI], 60-71%). Adjusting for clinical socio-economic covariates, associated better...